TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment options for patients with any T, any N, M1 disease
Source: Bladder Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage IV Bladder Cancer / Treatment Options for Stage IV Bladder Cancer
Treatment options for patients with any T, any N, M1 disease include:
Enfortumab vedotin plus pembrolizumab.
Source links and citations
Chemotherapy plus immunotherapy.
Source links and citations
Chemotherapy alone or as an adjunct to local treatment.
Source links and citations
Immunotherapy.
Source links and citations
EBRT for palliation.
Source links and citations
Urinary diversion or cystectomy for palliation.
Source links and citations
Other chemotherapy agents with activity in metastatic bladder cancer, such as paclitaxel, docetaxel, and ifosfamide (under clinical evaluation).[38,39][Level of evidence C3]
Source links and citations
Clinical trials.
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice